What are the main indications for pomalidomide?

Pomalidomide is a new type of immunomodulatory drug mainly used to treat relapsed or refractory multiple myeloma. This drug is indicated for patients with multiple myeloma who have received at least two prior treatments, including lenalidomide, and whose disease has progressed on or within 60 days of completing their last treatment.

Multiple myeloma is a malignant tumor that originates from plasma cells in the bone marrow, which proliferate abnormally and produce large amounts of monoclonal immunoglobulins. The disease causes bone destruction, pain, kidney damage, and abnormal functioning of the immune system. Pomalidomide helps control the development of multiple myeloma and alleviate disease symptoms by regulating the immune system, enhancing the activity of T cells and natural killer cells, and inhibiting the growth and angiogenesis of tumor cells.

Pomalidomide is often combined with other drugs such as dexamethasone to increase the effectiveness of the treatment. This combination treatment regimen has been extensively studied and has shown good efficacy and safety in clinical practice. The use of pomalidomide requires strict compliance with medical advice. The doctor will determine whether pomalidomide treatment is suitable for the patient based on the patient's medical history, health status, and specific characteristics of the disease, and develop a personalized treatment plan.

It is worth noting that pomalidomide may also cause some adverse reactions, such as hematological toxicity, gastrointestinal reactions, infection, etc. Therefore, the patient's response needs to be closely monitored during use and the drug dose adjusted or discontinued according to the specific situation. At the same time, the use of pomalidomide is strictly contraindicated for specific groups of people, such as pregnant women, lactating women, and men and women of childbearing potential.

Overall, pomalidomide is an important therapeutic agent that provides a new treatment option for patients with relapsed or refractory multiple myeloma. However, its use needs to be done with caution and under the guidance of a professional doctor.

xa0

Reference materials:https://go.drugbank.com/drugs/DB08910